Literature DB >> 24561124

CXCL12-induced upregulation of FOXM1 expression promotes human glioblastoma cell invasion.

Shengwen Wang1, Shanyi Zhang1, Junliang Li1, Xinke Xu1, Yinlun Weng1, Meiguang Zheng1, Leping Ouyang1, Fangcheng Li2.   

Abstract

Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor; it is highly aggressive and is associated with a poor prognosis. Binding of the chemokine CXCL12 to its receptors (CXCR4 and CXCR7) contributes to the activation of many downstream signaling pathways and promotes the invasion of various malignant tumor cells, including GBM cells. FOXM1, a transcription factor involved in cell cycle regulation, is overexpressed in GBM and is involved in GBM progression. However, the molecular mechanisms by which CXCL12 promotes the invasion of human GBM cells remain unclear. In this study, we demonstrate that CXCL12 increases the production of FOXM1 by binding to CXCR4 in GBM cell lines. Furthermore, pretreatment with an inhibitor of the PI3K/AKT pathway abrogated the CXCL12-induced expression of FOXM1. In addition, there was a positive correlation between CXCL12/CXCR4 expression and FOXM1 expression in human malignant glioma tissues. Finally, a functional assay revealed that CXCL12 does not stimulate GBM cell invasion when FOXM1 expression is silenced using a small interfering RNA (siRNA). Collectively, these findings suggest that CXCL12 promotes GBM cell invasion in part by increasing the expression of FOXM1, which is mediated in part by a PI3K/AKT-dependent mechanism in vitro.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CXCL12; Chemokine; FOXM1; Glioblastoma; Invasion

Mesh:

Substances:

Year:  2014        PMID: 24561124     DOI: 10.1016/j.bbrc.2013.12.079

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

Review 1.  G protein-coupled receptors as oncogenic signals in glioma: emerging therapeutic avenues.

Authors:  A E Cherry; N Stella
Journal:  Neuroscience       Date:  2014-08-24       Impact factor: 3.590

2.  Prospective Study of (68)Ga-NOTA-NFB: Radiation Dosimetry in Healthy Volunteers and First Application in Glioma Patients.

Authors:  Zhe Wang; Mingru Zhang; Liang Wang; Shengjun Wang; Fei Kang; Guoquan Li; Orit Jacobson; Gang Niu; Weidong Yang; Jing Wang; Xiaoyuan Chen
Journal:  Theranostics       Date:  2015-04-28       Impact factor: 11.556

3.  miR-137 acts as a tumor suppressor via inhibiting CXCL12 in human glioblastoma.

Authors:  Dehua Li; Wei Shan; Yan Fang; Pan Wang; Jicheng Li
Journal:  Oncotarget       Date:  2017-08-24

4.  Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2 promotes progression of human glioma.

Authors:  Xue Zhang; Qiao-Li Lv; Yuan-Tao Huang; Li-Hua Zhang; Hong-Hao Zhou
Journal:  J Exp Clin Cancer Res       Date:  2017-08-07

5.  FoxM1 drives ADAM17/EGFR activation loop to promote mesenchymal transition in glioblastoma.

Authors:  Chunli Zhang; Xiu Han; Xiao Xu; Zhengrong Zhou; Xi Chen; Yu Tang; Jie Cheng; Nida Fatima Moazzam; Fei Liu; Jing Xu; Wanxin Peng; Fengyi Du; Bin Zhang; Zhiwen Song; Jian Zeng; Aihua Gong
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

6.  CircPIK3C2A Facilitates the Progression of Glioblastoma via Targeting miR-877-5p/FOXM1 Axis.

Authors:  Jian Yang; Shuaiwei Tian; Baocheng Wang; Jiajia Wang; Liangliang Cao; Qinhua Wang; Wanqun Xie; Zhuangzhuang Liang; Heng Zhao; Yang Zhao; Keman Liao; Jie Ma
Journal:  Front Oncol       Date:  2021-12-24       Impact factor: 6.244

Review 7.  FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer.

Authors:  Cassie Liu; Carter J Barger; Adam R Karpf
Journal:  Cancers (Basel)       Date:  2021-06-19       Impact factor: 6.639

8.  CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.

Authors:  Ulrich Keller; Stefan Habringer; Richard Lewis; H Carlo Maurer; Nikita Singh; Irene Gonzalez-Menendez; Matthias Wirth; Markus Schick; Le Zhang; Konstandina Isaakidis; Anna Katharina Scherger; Veronika Schulze; Junyan Lu; Thorsten Zenz; Katja Steiger; Roland Rad; Leticia Quintanilla-Martinez; Marion Espeli; Karl Balabanian
Journal:  Leukemia       Date:  2021-08-06       Impact factor: 11.528

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.